Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.

Cooley B, Funkhouser W, Monroe D, Ezzell A, Mann DM, Lin FC, Monahan PE, Stafford DW.

Blood. 2016 Jul 14;128(2):286-92. doi: 10.1182/blood-2016-01-696104. Epub 2016 Apr 22.

2.

Extravascular FIX and coagulation.

Stafford DW.

Thromb J. 2016 Oct 4;14(Suppl 1):35. eCollection 2016. Review.

3.

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.

Toby GG, Liu T, Buyue Y, Zhang X, Bitonti AJ, Pierce GF, Sommer JM, Jiang H, Peters RT.

PLoS One. 2016 Feb 3;11(2):e0148255. doi: 10.1371/journal.pone.0148255. eCollection 2016.

4.

Prolonged activity of factor IX as a monomeric Fc fusion protein.

Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, Zarbis-Papastoitsis G, Reidy TJ, Merricks EP, Nichols TC, Bitonti AJ.

Blood. 2010 Mar 11;115(10):2057-64. doi: 10.1182/blood-2009-08-239665. Epub 2010 Jan 7.

5.

Dysfunctional Endogenous FIX Impairs Prophylaxis in a Mouse Hemophilia B Model.

Cooley B, Broze G Jr, Mann DM, Lin FC, Pedersen LG, Stafford DW.

Blood. 2019 Apr 16. pii: blood.2018884015. doi: 10.1182/blood.2018884015. [Epub ahead of print]

PMID:
30992271
6.

Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.

Monahan PE, Sun J, Gui T, Hu G, Hannah WB, Wichlan DG, Wu Z, Grieger JC, Li C, Suwanmanee T, Stafford DW, Booth CJ, Samulski JJ, Kafri T, McPhee SW, Samulski RJ.

Hum Gene Ther. 2015 Feb;26(2):69-81. doi: 10.1089/hum.2014.106. Epub 2015 Jan 21.

7.

Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.

Nolte MW, Nichols TC, Mueller-Cohrs J, Merricks EP, Pragst I, Zollner S, Dickneite G.

J Thromb Haemost. 2012 Aug;10(8):1591-9. doi: 10.1111/j.1538-7836.2012.04826.x.

8.

Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.

Lissitchkov T, Matysiak M, Zavilska K, Laguna P, Gercheva L, Antonov A, Moret A, Caunedo P, Aznar JA, Woodward MK, Páez A.

Haemophilia. 2013 Sep;19(5):674-8. doi: 10.1111/hae.12148. Epub 2013 May 7.

PMID:
23647607
9.

Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.

Zhang Y, Roberts J, Bensen-Kennedy D, Jacobs I, Santagostino E, Voigt C, Feussner A, Morfini M, Sidhu J.

J Thromb Haemost. 2016 Nov;14(11):2132-2140. doi: 10.1111/jth.13444. Epub 2016 Oct 3.

10.

Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.

Lambert T, Recht M, Valentino LA, Powell JS, Udata C, Sullivan ST, Roth DA.

Haemophilia. 2007 May;13(3):233-43. Erratum in: Haemophilia. 2007 Jul;13(4):450.

PMID:
17498071
11.

Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.

Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S.

Thromb Haemost. 2009 Oct;102(4):634-44. doi: 10.1160/TH09-04-0255.

PMID:
19806248
12.

Prophylaxis in factor IX deficiency product and patient variation.

Kisker CT, Eisberg A, Schwartz B; Mononine Study Group.

Haemophilia. 2003 May;9(3):279-84.

PMID:
12694518
13.

Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.

Sommer JM, Buyue Y, Bardan S, Peters RT, Jiang H, Kamphaus GD, Gray E, Pierce GF.

Thromb Haemost. 2014 Nov;112(5):932-40. doi: 10.1160/TH13-11-0971. Epub 2014 Aug 21.

14.

In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.

Enjolras N, Perot E, Le Quellec S, Indalecio A, Girard J, Negrier C, Dargaud Y.

Haemophilia. 2015 Jul;21(4):e317-21. doi: 10.1111/hae.12688. Epub 2015 May 15.

PMID:
25981983
15.

Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.

Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC Jr, Garzone PD, Schaub RG.

Blood. 1996 Oct 1;88(7):2603-10.

16.

Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.

Tortella BJ, Alvir J, McDonald M, Spurden D, Fogarty PF, Chhabra A, Pleil AM.

J Manag Care Spec Pharm. 2018 Jul;24(7):643-653. doi: 10.18553/jmcp.2018.17212. Epub 2018 Jan 24.

17.

Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.

Perot E, Enjolras N, Le Quellec S, Indalecio A, Girard J, Negrier C, Dargaud Y.

Thromb Res. 2015 May;135(5):1017-24. doi: 10.1016/j.thromres.2015.02.034. Epub 2015 Mar 10.

PMID:
25795563
18.

Recombinant FIXFc: a novel therapy for the royal disease?

Valentino LA.

Expert Opin Biol Ther. 2011 Oct;11(10):1361-8. doi: 10.1517/14712598.2011.603304. Epub 2011 Jul 22. Review.

PMID:
21780945
19.

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, Novitzky N, Wong RS, Krassova S, Allen G, Jiang H, Innes A, Li S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Nugent K, Vigliani G, Brennan A, Luk A, Pierce GF; B-LONG Investigators.

N Engl J Med. 2013 Dec 12;369(24):2313-23. doi: 10.1056/NEJMoa1305074. Epub 2013 Dec 4.

20.

Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.

Alamelu J, Bevan D, Sorensen B, Rangarajan S.

J Thromb Haemost. 2014 Dec;12(12):2044-8. doi: 10.1111/jth.12756. Epub 2014 Nov 11.

Supplemental Content

Support Center